Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma

This study has been completed.
Sponsor:
Collaborators:
El-Nour eye hospital
Kasr El-Ainy Eye hospital
Information provided by:
Cairo University
ClinicalTrials.gov Identifier:
NCT01051583
First received: January 7, 2010
Last updated: January 15, 2010
Last verified: December 2007

January 7, 2010
January 15, 2010
January 2006
April 2008   (final data collection date for primary outcome measure)
Disappearance of iris neovessels [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01051583 on ClinicalTrials.gov Archive Site
Intra ocular pressure [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma
Avastin as an Adjunct to Diode Laser Cyclophotoablation in the Treatment of Neovascular Glaucoma

Assess the efficacy of Avastin as an adjunct to Diode Laser cyclophotocoagulation in the treatment of Neovascular Glaucoma.

Design: Prospective, comparative interventional case series. Method: Patients were randomly assigned into Group A which were treated with Diode laser cyclophotocoagulation alone, whereas group B received intravitreal Avastin (One milligram = 0.04mL of 25 mg/mL) in conjunction with the Diode Laser. The preoperative data included etiology, mean age; follow up period, and a full ophthalmological examination with emphasis on mean IOP, iris neovascularization, pain and corneal edema.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Neovascular Glaucoma
Procedure: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin
The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
Other Name: bevacizumab
  • Experimental: Avastin , diode laser cyclophotcoagulation
    Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation
    Intervention: Procedure: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin
  • Active Comparator: Diode Laser cyclophotocoagulation
    Diode laser cyclophotocoagulation to control intraocular pressure
    Intervention: Procedure: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
April 2008
April 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Neovascular absolute glaucoma
  • Painful blind eyes

Exclusion Criteria:

  • Neovascular glaucoma with useful vision or potential for useful vision
Both
14 Years to 72 Years
No
Contact information is only displayed when the study is recruiting subjects
Egypt
 
NCT01051583
NVG AV1
Yes
Dr.Mostafa Aly EL-Helw assistant professor, Cairo university, school of medicine, ophthalmology departement. El-Nour Eye hospital
Cairo University
  • El-Nour eye hospital
  • Kasr El-Ainy Eye hospital
Principal Investigator: Mostafa A EL-Helw, M.D. Cairo University
Cairo University
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP